Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
increasingly used for advanced non-small cell lung cancer (NSCLC) as first-line therapy …

Gefitinib and erlotinib are the first-line tyrosine kinase inhibitors (TKI) for advanced non-
small-cell lung cancer. However, co-administration of either drug with proton pump inhibitors …

Purpose Concurrent proton pump inhibitor (PPI) use might reduce the plasma concentration
of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Clinically, the …

Background The use of gastric acid suppressants (GASs) has an influence on the exposure
of some epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and …

Purpose This study aimed to examine the prognostic impact of concomitant pH-regulating
drug use in patients with epidermal growth factor receptor (EGFR)-mutation-positive non …

Abstract Background Tyrosine-kinase inhibitors (TKIs) markedly improve progression-free
survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) mutated for …

Background This retrospective cohort study examined the impact of tetracyclines (TCs) and
proton pump inhibitors (PPIs) alone or in combination on the efficacy of epidermal growth …

Background Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and
histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of …

Introduction Dacomitinib and gefitinib are irreversible epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKI) indicated for the first-line treatment of patients with …

Purpose: Erlotinib and gefitinib are both tyrosine kinase inhibitors (TKIs) approved for the
treatment of non-small cell lung cancer (NSCLC). Although it is well known that the increase …